RESUMEN
A six-year-old atopic boxer presented with pigmented viral plaques on the interdigital spaces and pinnae following treatment with potent topical glucocorticoids. The lesions regressed after treatment was discontinued, and recurred each time a topical glucocorticoid was resumed. A Chipapillomavirus was amplified from lesional tissue.
RESUMEN
BACKGROUND: Oclacitinib administered at the licensed dose twice daily for two weeks and then once daily as required is recommended for the treatment of atopic dogs. In some cases, the once-daily regimen is insufficient to control the clinical signs. OBJECTIVES: To provide preliminary safety and efficacy data on the prolonged twice-daily administration of oclacitinib in atopic dogs. ANIMALS: Fifty-three client-owned atopic dogs. METHODS AND MATERIALS: The medical records of dogs with atopic dermatitis treated with oclacitinib twice daily for more than two weeks were reviewed retrospectively. Animal details, treatment dose and duration, concurrent diseases, adjunctive medications and possible adverse events were recorded. Treatment efficacy was assessed retrospectively and, when available, the selected blood parameters before and during the treatment were compared. Statistical analyses of the collected data were performed. RESULTS: The median treatment duration was 113 days. Excellent-to-good efficacy was observed in 38 dogs (72%), including 24 of 33 dogs that failed to respond to the once-daily regimen. Eight dogs showed a poor response despite the addition of systemic glucocorticoids. Pyoderma, gastrointestinal signs and otitis externa were the most frequent adverse events recorded whilst on treatment. Blood tests performed in 35 dogs showed slightly decreased leucocyte, neutrophil, eosinophil and monocyte counts that remained within the reference ranges in most cases. Three dogs developed hypercholesterolemia. CONCLUSIONS AND CLINICAL RELEVANCE: Prolonged twice-daily administration of oclacitinib generally was well-tolerated and was effective in most of the treated dogs. Regular clinical evaluation and blood tests are advisable for this treatment regimen.
Asunto(s)
Dermatitis Atópica , Fármacos Dermatológicos , Enfermedades de los Perros , Animales , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/veterinaria , Enfermedades de los Perros/inducido químicamente , Enfermedades de los Perros/tratamiento farmacológico , Perros , Pirimidinas , Estudios Retrospectivos , SulfonamidasRESUMEN
Erythema multiforme (EM), an uncommon immune-mediated skin disorder of cats, conceivably could be triggered by feline herpesvirus type-1 (FHV-1) infection, in a manner analogous to human herpesvirus-associated EM (HAEM). This report describes a 10-year-old Persian-mixed cat with a presumptive diagnosis of HAEM.
L'érythème polymorphe (EM), est une dermatose à médiation immune rare chez le chat, théoriquement déclenché par une infection FHV-1 (feline herpesvirus type-1), de la même façon que chez l'homme avec HAEM (human herpesvirus-associated EM). Cet article décrit un chat croisé Persan de 10 ans avec un diagnostic présumé de HAEM.
El eritema multiforme (EM), un trastorno cutáneo poco común mediado por el sistema inmunitario de los gatos que posiblemente podría desencadenarse por una infección por herpesvirus felino tipo 1 (FHV-1), de manera análoga a la EM asociada al herpesvirus humano (HAEM). Este informe describe un gato persa mixto de 10 años con un diagnóstico presuntivo de HAEM.
Eritema multiforme (EM), uma doença de pele imunomediada incomum em gatos, em teoria pode ser desencadeada por infecção por herpesvírus felino tipo 1 (FHV-1), de maneira análoga ao EM associado ao herpesvírus humano (EMAH). Este relato de caso descreve um gato persa de 10 anos de idade com diagnóstico presuntivo de EMAH.